drugset
drugset / Trial / NCT04219969

FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

NCT04219969 ↗

Completed 11 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.

Timeline

Start
2018-09-21
Primary completion
2024-05-07
Completion
2024-05-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent — Intravenous

Indications

spinal cord neoplasm